Antiphospholipid Syndrome : 30 Years On – Dr. Graham Hughes
Professor Graham Hughes is a Consultant Rheumatologist and the founder and editor of the international journal ‘LUPUS,’ and Head ofLondon Lupus Centre. In 1983 he described the clotting disorder now known as Hughes Syndrome for which he received the World Rheumatology (ILAR) Research Prize in 1993.
Author Quotes :
We became interested in a disease called ‘Jamaican Neuropathy’–an acute transverse myelitis. These women end up in wheelchairs with paraplegia, and they are interesting because they have a false positive VDRL and they are ANA positive.
If you take recurrent pregnancy loss, 12% of all cases. If you take stroke, 14%–if it’s young stokes, 25%.
Moving right forward now to modern treatment, not just warfarin and so on, but possible antibiologics–antibodies to some of the bad guys in this disease… and this is where we are at the moment, to see whether these in fact affect the clotting mechanism in this disease.
Professor Hughes begins his presentation with an overview of his Lupus Centre clinics and takes a look at the past, present, and what the future holds for antiphospholipid syndrome (APS).
He recounts his experiences over the years with patients and how studies of lupoid sclerosis led to setting up assays for antiphospholipid antibodies.
Continuing along the dateline, Prof Hughes describes the criteria thought to be important for the identification of anticardiolipin syndrome which led to the world’s first symposium on antiphospholipid antibodies.
Moving on to the present day, he covers the up-to-date literature statistics for pregnancy loss, stroke, heart attack, and DVT relating to APS. Discussing how the science has moved on, he demonstrates how antibodies are directed against phospholipid binding proteins.
Concluding this video excerpt of his presentation, Prof Hughes discusses possible therapeutic targets for the future.
Take Home Messages :
1) Many case reports describe lupus with various clotting problems.
2) Attendance numbers at the most recent international congress on antiphospholipid antibodies shows increasing recognition and awareness among doctors.
3) Beta-2 glycoprotein 1 removes cellular debris and is a very important molecule in the body.